Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of OBP-301 plus radiotherapy in locally advanced esophageal cancer
jRCT1080225033Phase 2Completed
- Sponsor
- Oncolys BioPharma Inc.
- Start
- Jan 2020
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of suratadenoturev in esophageal cancer, sponsored by Oncolys BioPharma Inc. Started Jan 2020; status: completed.
02
Drugs
suratadenoturev
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on jRCT1080225033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080225033.